Epidermal growth factor receptor signaling in nonsmall cell lung cancer (Q39752055)

14 September 2017

title

Epidermal growth factor receptor signaling in nonsmall cell lung cancer (English)

1 reference

14 September 2017

1

0 references

publication date

1 June 2010

1 reference

14 September 2017

1 reference

14 September 2017

volume

28

1 reference

14 September 2017

issue

5

1 reference

14 September 2017

page(s)

515-525

1 reference

Review of epidermal growth factor receptor biology

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Activation of tyrosine kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor receptors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Targeting the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

A comprehensive pathway map of epidermal growth factor receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor receptor inhibition and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Molecular targets of the oncogenic transcription factor jun.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

PI3K-Akt pathway: its functions and alterations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Akt activation by growth factors is a multiple-step process: the role of the PH domain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

The life of a cell: apoptosis regulation by the PI3K/PKB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Control of apoptosis and mitotic spindle checkpoint by survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Survivin is required for stable checkpoint activation in taxol-treated HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Protein factors which regulate cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Overexpression of EGFR and c‐erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor receptor family in lung cancer and premalignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

EGFR and erbB2 mutation status in Japanese lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor inhibition in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Inhibition of Tumor Growth by Ribozyme-Mediated Suppression of Aberrant Epidermal Growth Factor Receptor Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

The epidermal growth factor receptor as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Studies with ZD1839 in preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Genomic signatures to guide the use of chemotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Clinical experience with gefitinib: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Resolving the Optimal Timing of Radiotherapy After Radical Prostatectomy: The Need for Further Research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells☆☆☆

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

ZD1839 ('Iressa') as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357900903476760

10.3109/07357900903476760

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference